Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
53 Cards in this Set
- Front
- Back
2 major pathways that arachidonic acid enters?
|
lipoxygenase
cyclo-oxygenase |
|
lipoxygenase produces?
|
leukotrienes (LTB4, LTC4/B4/E4)
|
|
cyclo-oxygenase produces?
|
prostaglandins
thromboxane prostacyclin |
|
COX1?
|
housekeeping enzyme, present in most cells
|
|
COX2?
|
only in setting of inflammation
|
|
NSAIDs major differences from narcotic analgesics?
|
1.lower maximal effect
2.no addiction 3.free of CNS effects |
|
mechanism of NSAIDs?
|
inhibition of PG biosynthesis by COX1 and COX2
|
|
therapeutic uses of NSAIDs?
|
analgesic
antipyretic anti-inflammatory primary dysmenorrhea patent ductus arteriosus colon cancer |
|
side effects of NSAIDs?
|
GI ulceration and intolerance;
blockade of platelet aggregation; inhibition of uterine motility; inhibition of PG-mediated renal effects; hypersensitivity reaction |
|
characteristics of hypersensivity reactions to NSAIDs?
|
asthmatic attacks;
urticaria; angioedema; cross reactivity to all aspirin-like drugs |
|
warning on package insert of NSAIDs?
|
GI toxicity such as bleeding, ulcer, and perforation
|
|
misoprostol?
|
synthetic PGE1 analog given with NSAIDs to protect GI mucosa;
side effect is diarrhea |
|
given with NSAIDs to protect GI mucosa?
|
misoprostol
|
|
advantage in terms of side effects of selective COX2 inhibitors?
|
no gastric ulceration and intolerance; no inhibition of platelet function
|
|
aspirin mechanism of action and importance?
|
irreversible acetylation of cyclooxygenase;
platelet effects persist for lifetime of platelet (8-10 days) - surgical considerations |
|
early, reversible warning of aspirin toxicity?
|
tinnitus or deafness
|
|
aspirin intoxication?
|
disturbance of acid-base balance (resp alkalosis followed by metabolic acidosis);
salicylism: headache, dizziness, tinnitus, mental confusion, drowsiness, sweating |
|
contraindications for aspirin?
|
ulcer
asthma gout influenza (Reye's syndrome) |
|
diflunisal?
|
antiinflammatory potency >aspirin;
not given for analgesic or antipyretic; less auditory side effects |
|
mesalamine?
|
salicylate;
used for local effect in IBD |
|
acetaminophen?
|
analgesic and antipyretic, weak anti-inflammatory
|
|
adverse effect of acetaminophen?
|
fatal hepatic necrosis
|
|
antidote to acetaminophen toxicity?
|
mucomyst (N-acetylcysteine)
|
|
mucomyst (N-acetylcysteine)?
|
antidote to acetaminophen toxicity
|
|
justification for giving N-acetylcysteine for acetaminophen toxicity?
|
gives body more cysteine to make more glutathione to process toxic intermediates to a safer metabolite that can be excreted
|
|
what condition increases risk of acetaminophen toxicity and why?
|
chronic alcoholism;
induction of p450 enzyme that processes acetaminophen to a toxic intermediate |
|
therapeutic uses of indomethacin?
|
acute gout and ankylosing spondylitis;
patent ductus arteriosus in premature infants |
|
adverse effects of indomethacin?
|
GI: nausea, vomiting, anorexia, abdominal pain;
CNS: severe frontal headache (15-25%), may be associated with dizziness, confusion, depression |
|
sulindac?
|
prodrug NSAID;
less ulcerogenic potential, GI irritation, and blood loss are less severe than aspirin |
|
therapeutic uses of tolmetin?
|
JRA
not gout |
|
diclofenac mechanism?
|
reduce synthesis of both PG and leukotrienes
|
|
toxic effects of diclofenac?
|
GI
hepatotoxicity |
|
1st injectable NSAID?
|
ketorolac
|
|
ketorolac indications?
|
short-term (<5 days) managment of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting
|
|
naproxen advantage over aspirin?
|
less GI irritation but 20x more potent than aspirin
|
|
ketoprofen mechanism of action?
|
inhibits both cyclooxygenases and lipoxygenase
|
|
oxaprozin?
|
long half life (40-60 hrs) resulting in increased patient compliance
|
|
piroxicam mechanism?
|
potent reversible inhibitor of cyclooxygenase
|
|
piroxican half life and consequence?
|
extended half-life (50-60 hrs) with steady state concentration reached at 7-12 days
|
|
meloxicam mechanism?
|
preferentially inhibit COX2 over COX1
|
|
only nonacid NSAID?
|
nabumetone
|
|
nabumetone?
|
nonacid NSAID;
ketone prodrug; preferentially inhibits COX2 (at low dose) |
|
only COX2 selective inhibitor still on market?
|
celecoxib
|
|
celecoxib?
|
COX2 selective inhibitor resulting in fewer ulcers and no effect on platelet aggregation or prothrombin time
|
|
why was rofecoxib (vioxx) removed from the market?
|
cardiovascular event
|
|
indications for disease modifying antirheumatic drugs?
|
patients who are refractory to therapeutic regimens of NSAIDs
|
|
associated with fatal infusion reactions?
|
rituximab
|
|
abatacept mechanism and administration method?
|
inhibit T cell activation;
IV injection |
|
rituximab mechanism and administration method?
|
chimeric monoclonal antibody specific to the antigen CD20 B lymphocytes
|
|
etanercept mechanism and administration method?
|
bind to TNF and block interaction with cell surface TNF receptors;
SC |
|
adalimumab mechanism, administration method, and half life?
|
bind to TNF-α and block interaction with p55 and p75 cell surface TNF receptors;
SC; half life = 10-20 days |
|
infliximab mechanism and administration method?
|
binds to soluble and membrane-bound TNF-α and inhibits binding of TNF-α with its receptors;
IV |
|
Other disease modifying antirheumatic drugs?
|
methotrexate and other immunosuppressive drugs;
antimalarial drugs (chloroquine, hydroxychloroquine); sulfaxalazine; penicillamine; gold |